No Data
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
Express News | EXCLUSIVE: Cybin Tells Benzinga 'The Company Is Evaluating Non-hallucinogenic Dosing of CYB005 Preclinical Candidate Molecules for the Treatment of CNS Disorders'
Express News | EXCLUSIVE: Cybin Tells Benzinga Co. Announces Grant Of First U.S Composition of Matter Patent N Support Of Its CYB005 Phenethylamines Program
FDA Is Said to See "Path Forward" for Ecstasy-based Drug
Bright Minds Rally Ends as Psychedelic Stocks Extend Volatility
Cybin Inc. CEO to Speak at Research Event
loading...
No Data
No Data
